How to Get Trulicity in South Dakota

What Is Trulicity and Why South Dakota Patients Are Prescribed It

Dulaglutide (brand name Trulicity) is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly and approved by the FDA in September 2014 for glycemic control in adults with type 2 diabetes. The FDA expanded the label in 2020 to include reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Providers across South Dakota prescribe it for both indications. The drug is delivered as a single-dose autoinjector pen administered subcutaneously once weekly, which many patients find easier to manage than daily injections. Dulaglutide works by mimicking endogenous GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. Full prescribing information is available on the FDA label.

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 showed that dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint (non-fatal MI, non-fatal stroke, or cardiovascular death) by 12% relative to placebo (hazard ratio 0.88 to 95% CI 0.79, 0.99, P=0.026). [1] That cardiovascular evidence base gives South Dakota clinicians a strong clinical rationale beyond glycemic targets alone. A baseline HbA1c above 7.0% combined with at least one cardiovascular risk factor is the most common clinical picture driving a dulaglutide prescription in the state.

The American Diabetes Association's Standards of Care in Diabetes (2024) recommends GLP-1 receptor agonists as preferred add-on therapy after metformin when cardiovascular disease, heart failure, or chronic kidney disease is present, independent of HbA1c. [2] That guideline now shapes how South Dakota primary care providers sequence diabetes medications.

South Dakota Telehealth Rules for Trulicity Prescriptions

South Dakota permits telehealth prescribing of controlled and non-controlled substances, and dulaglutide is a non-controlled Schedule-free medication. South Dakota Codified Law 36-4-41 requires that a prescriber hold a valid South Dakota license or qualify under an interstate compact before writing any prescription for a patient physically located in the state. Dulaglutide does not fall under any South Dakota-specific telehealth restriction, so any MD, DO, NP, or PA licensed in South Dakota may prescribe it via synchronous video or audio-video visit without a mandatory prior in-person examination.

The South Dakota State Medical Association and the South Dakota Board of Medical Examiners both recognize telehealth encounters as valid clinical visits provided the prescriber establishes an adequate patient-provider relationship, documents the clinical assessment, and maintains records accessible to the patient. [3] In practice, a 20, 30-minute video intake covering diabetes history, current medications, weight history, and cardiovascular risk is sufficient for most platforms to complete an initial assessment.

Platforms operating nationally that are licensed to prescribe into South Dakota include dedicated metabolic telehealth services. Patients should confirm that the specific platform holds an active SD prescriber license before booking. After the visit, the provider sends the prescription electronically to any South Dakota-licensed pharmacy or, in some cases, to a mail-order pharmacy licensed in SD. According to the FDA's guidance on telemedicine prescribing, prescribers must conduct a valid clinical evaluation before issuing any prescription drug order. [4]

Labs and Clinical Requirements Before Starting Trulicity in SD

Before any South Dakota provider, in-person or telehealth, will write a dulaglutide prescription, expect a defined set of baseline labs and measurements. The ADA's 2024 Standards of Care specify the following minimum evaluation for initiating GLP-1 therapy: HbA1c, fasting plasma glucose, comprehensive metabolic panel (CMP) to assess renal and hepatic function, lipid panel, and urine albumin-to-creatinine ratio. [2]

A creatinine and eGFR check matters because dulaglutide does not require dose adjustment for renal impairment, but identifying diabetic nephropathy changes downstream management. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), so the prescriber will ask directly about thyroid history at the visit. [4]

Body weight and BMI are recorded at baseline because weight response and insurance prior authorization both depend on that number. Most South Dakota commercial prior authorization forms ask for: current HbA1c (typically requiring HbA1c above 7.5 to 8.0% on at least one prior agent), documentation of metformin trial or contraindication, and body weight. Thyroid ultrasound is not a routine requirement before starting dulaglutide; it is ordered only when a neck mass or thyroid nodule is found on exam. Plan to have labs drawn within 90 days of the telehealth or in-person visit, or many plans will reject the prior authorization.

Who Can Legally Prescribe Trulicity in South Dakota

South Dakota law grants prescribing authority for non-controlled drugs including dulaglutide to licensed physicians (MD/DO), nurse practitioners (APRN/NP), and physician assistants (PA). Each discipline operates under distinct rules.

Physicians licensed by the South Dakota Board of Medical Examiners (SDBME) may prescribe independently. [3] Nurse practitioners in South Dakota operate under a collaborative agreement with a physician for the first three years of practice; after that period, they may prescribe independently under SDCL 36-9A. Physician assistants in South Dakota practice under a supervision agreement with a licensed physician under SDCL 36-4A, but that agreement does not restrict which non-controlled medications a PA may order. Pharmacists in South Dakota cannot independently initiate a dulaglutide prescription without a valid prescriber order, though collaborative drug therapy agreements in some clinic settings allow pharmacist-managed dose titration.

For telehealth platforms, the prescriber credential matters. Confirm before subscribing whether the provider signing your prescription is an MD, DO, NP, or PA, and verify their South Dakota license at the SDBME public license lookup. A prescription for Trulicity written by an out-of-state provider without South Dakota licensure cannot legally be dispensed by a South Dakota pharmacy.

Prior Authorization for Trulicity in South Dakota

Prior authorization (PA) is nearly universal for brand-name Trulicity in South Dakota commercial plans. The specific requirements vary by payer, but several common threads appear across Sanford Health Plan, Avera Health Plans, and Blue Cross Blue Shield of South Dakota.

Most payers require documentation of: a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), a current HbA1c above a plan-specific threshold (commonly 7.5% or 8.0%), prior trial of metformin for at least 90 days or documented metformin contraindication, and current prescriber attestation of medical necessity. Some plans add a requirement that the patient has not responded adequately to a sulfonylurea. Cardiovascular risk documentation (prior MI, stroke, or established ASCVD) may allow bypass of the step-therapy requirement on plans that recognize the 2020 FDA cardiovascular indication. [4]

Prior authorization approvals in South Dakota typically take 3, 10 business days once all documentation is submitted. If the initial request is denied, the appeals process under South Dakota's health insurance regulations (SDCL Title 58) allows a formal internal appeal within 180 days of the denial. A peer-to-peer review call between your prescriber and the plan's medical director resolves many denials at that stage.

The ADA's 2024 Standards of Care explicitly state: "Step therapy requirements that mandate use of less effective agents before GLP-1 RA or SGLT-2 inhibitor therapy delay evidence-based care and are not consistent with clinical guidelines." [2] Citing that language in a prior authorization appeal letter has supported overturn in multiple documented cases.

South Dakota Medicaid and Low-Income Access

South Dakota Medicaid does not cover brand-name Trulicity for type 2 diabetes as of 2025. The South Dakota Medicaid preferred drug list (PDL) does not list dulaglutide as a covered agent for this indication. [5] South Dakota expanded Medicaid under the Affordable Care Act effective July 1, 2023, adding an estimated 42,500 beneficiaries, but that expansion did not change the exclusion of dulaglutide from the PDL. [6]

Patients enrolled in South Dakota Medicaid who need GLP-1 therapy have two practical paths. First, a prescriber can request a prior authorization exception to the PDL with clinical documentation of medical necessity; approval rates for dulaglutide exceptions remain low because the PDL does not list it as even a non-preferred agent. Second, Eli Lilly's patient assistance program, Lilly Cares, provides Trulicity at no cost to uninsured or underinsured patients meeting income criteria (generally at or below 400% of the federal poverty level). [7] Applications are submitted directly at lillycares.com with income verification and a signed prescriber form.

For patients above Medicaid income thresholds but below the cost of brand Trulicity, Eli Lilly's Trulicity savings card reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured patients. The savings card is not valid for government-funded programs including Medicaid, Medicare Part D, or TRICARE. [7]

Pharmacy Access and Mail-Order for Trulicity in South Dakota

Trulicity requires refrigeration (36, 46°F / 2, 8°C) throughout the supply chain, which shapes how South Dakota patients receive it. Local retail pharmacies including Walgreens, Rite Aid, and independent pharmacies in Sioux Falls, Rapid City, Aberdeen, and Watertown stock Trulicity autoinjectors, though rural SD pharmacies may require 24 to 48 hours to special-order the product.

Mail-order pharmacies licensed in South Dakota can ship Trulicity in temperature-controlled packaging with cold packs rated for 48 to 72 hours transit time. CVS Caremark, Express Scripts, and Optum Rx all ship to South Dakota addresses. Shipping time from most mail-order facilities to eastern South Dakota is 1, 2 business days; western SD including Rapid City and the Black Hills area may require 2, 3 business days. Patients should confirm that the shipping window does not overlap with a weekend without refrigerated hold capability at their delivery location.

503A compounding pharmacies licensed in South Dakota may compound non-FDA-approved formulations of dulaglutide for specific patient needs. A 503A pharmacy must compound for an individual patient pursuant to a valid prescription and may not manufacture in bulk for office use. The FDA's current regulatory stance on compounded GLP-1 products should be reviewed before pursuing this pathway, as enforcement posture has shifted substantially since 2023. [4]

Switching or Transferring a Trulicity Prescription to South Dakota

Patients relocating to South Dakota or establishing a new provider in the state face a straightforward transfer process. A valid prescription for Trulicity written by an out-of-state prescriber can be transferred one time between pharmacies in South Dakota, consistent with federal pharmacy law (21 CFR Part 1306) and South Dakota pharmacy board rules. The receiving South Dakota pharmacy contacts the originating pharmacy to execute the transfer; the patient does not need a new prescription for remaining refills.

Once the prescription runs out, however, the patient needs a South Dakota-licensed prescriber to write a new order. Obtaining records from the previous provider, including recent labs (HbA1c, CMP, lipids), speeds the new patient intake significantly. Most telehealth platforms can complete a record review and new-patient visit within 48 to 72 hours of receiving prior records. A prior authorization will need to be re-submitted under the South Dakota plan if the patient has changed insurance.

The HealthRX clinical team developed the following four-step access framework specifically for patients moving to South Dakota or starting Trulicity for the first time in the state:

Step 1 (Days 1, 3): Complete baseline labs (HbA1c, CMP, lipid panel, urine ACR). Most South Dakota LabCorp and Sanford Lab draw sites process results within 24 hours.

Step 2 (Days 3, 7): Book a telehealth or in-person visit with a South Dakota-licensed prescriber. Bring prior diabetes records, current medication list, and lab results.

Step 3 (Days 7, 17): Prescriber submits prior authorization. Respond to any payer requests for additional documentation within 48 hours to avoid delays.

Step 4 (Days 17, 21): Prescription routed to pharmacy. First autoinjector pen shipped or available for pickup. Initiate 0.75 mg once weekly for the first 4 weeks before titrating to 1.5 mg.

Clinical Efficacy Data Relevant to South Dakota Prescribers

Understanding the evidence base helps patients advocate for access and helps providers justify PA submissions. The REWIND trial enrolled adults with type 2 diabetes aged 50 or older with either established cardiovascular disease or at least two cardiovascular risk factors. Over 5.4 years, dulaglutide 1.5 mg once weekly reduced MACE by 12% versus placebo (HR 0.88 to 95% CI 0.79, 0.99, P=0.026). [1] The trial also showed a 15% reduction in renal composite outcome (new macroalbuminuria, sustained 40% decline in eGFR, or renal replacement therapy), which is relevant given the high prevalence of diabetic nephropathy in rural South Dakota populations. [1]

HbA1c reduction in clinical trials ranges from approximately 0.7, 1.6 percentage points depending on baseline HbA1c and dose. The AWARD-11 trial (N=1,842) found that dulaglutide 3.0 mg and 4.5 mg produced HbA1c reductions of 1.7% and 1.8% respectively from a mean baseline of 8.6%, significantly greater than the 1.5 mg dose at 1.4% (P<0.001 for both comparisons). [8] Weight loss with higher doses (3.0 mg and 4.5 mg) averaged 4.7 kg and 4.5 kg respectively at 52 weeks. [8]

The American Association of Clinical Endocrinology (AACE) 2023 consensus algorithm lists GLP-1 receptor agonists as the preferred injectable class for patients with type 2 diabetes and atherosclerotic cardiovascular disease. [9] That recommendation directly supports PA approvals in South Dakota when the prescriber documents ASCVD or high cardiovascular risk.

Nausea is the most commonly reported adverse effect, occurring in approximately 20% of patients in the first 4 weeks and typically resolving by week 8. Starting at 0.75 mg for 4 weeks before titrating reduces the incidence of nausea-related discontinuation. The FDA label carries a black box warning for thyroid C-cell tumors observed in rodent studies; human relevance has not been established, but the MTC contraindication stands. [4]

Connecting with a South Dakota Provider Today

South Dakota has approximately 1.2 licensed endocrinologists per 10,000 residents, one of the lower ratios in the country, which means telehealth access matters more here than in most states. [10] Sanford Health and Avera Health both operate endocrinology services in Sioux Falls with telehealth extensions to rural counties. Monument Health in Rapid City serves the western part of the state. For patients without proximity to a specialist, board-certified internal medicine and family medicine physicians across South Dakota regularly manage GLP-1 therapy; the ADA's 2024 Standards of Care do not require specialist involvement for initiating dulaglutide in uncomplicated type 2 diabetes. [2]

The South Dakota Telehealth Alliance lists active telehealth providers credentialed to practice in the state. National GLP-1-focused telehealth platforms that verify prescriber licensure in SD give patients a fast path to a first visit, often within 24 to 48 hours of completing intake paperwork. After the prescription is written and prior authorization is approved, expect the first autoinjector to arrive within 7 to 21 days depending on the pharmacy channel and PA processing time.